EnVVeno Medical Corporation (NASDAQ:NVNO) | Finanzwire

Basculer en Français

8630	Companies
143980	Keywords
79657	Articles
76974	Press releases

Headlines Articles Press releases EnVVeno Medical Corporation

Home
Companies
EnVVeno Medical Corporation

BRIEF

published on 10/28/2024 at 13:35, 5 months 30 days ago

EnVVeno Medical Commences Pre-Clinical Study for enVVe Valve

FDA Approval EnVVeno Medical CVI Treatment GLP Study EnVVe Valve
PRESS RELEASE

published on 10/28/2024 at 13:30, 5 months 30 days ago

enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R)
enVVeno Medical Corporation successfully completes first wave of implants with updated delivery system for enVVe replacement venous valve, on track for U.S. pivotal trial in mid-2025

EnVVeno Medical Corporation Venous Disease Implants EnVVe Pivotal Trial
BRIEF

published on 09/27/2024 at 03:23, 7 months ago

EnVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering

Public Offering EnVVeno Medical VenoValve Venous Disease Titan Partners Group
PRESS RELEASE

published on 09/27/2024 at 03:18, 7 months ago

enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering
enVVeno Medical Corporation announces pricing of underwritten public offering for the treatment of venous disease. Offering led by Titan Partners Group. Expected gross proceeds of $15.0 million

Public Offering Gross Proceeds EnVVeno Medical Corporation Venous Disease Titan Partners Group
BRIEF

published on 09/26/2024 at 22:10, 7 months ago

EnVVeno Medical Corporation Announces Proposed Public Offering

SEC Filing Public Offering EnVVeno Medical VenoValve Venous Disease
PRESS RELEASE

published on 09/26/2024 at 22:05, 7 months ago

enVVeno Medical Corporation Announces Proposed Public Offering
enVVeno Medical Corp. proposes public stock offering through underwritten public offering for venous disease treatment products. Funding for R&D and corporate needs

Medical Devices EnVVeno Medical Corporation Venous Disease Treatment Public Stock Offering R&D Funding
BRIEF

published on 09/03/2024 at 15:05, 7 months 24 days ago

EnVVeno Medical Appoints Sandy Prietto as VP of Marketing

Medical Devices FDA Approval EnVVeno Medical VenoValve Sandy Prietto
PRESS RELEASE

published on 09/03/2024 at 15:00, 7 months 24 days ago

enVVeno Medical Adds Sandy Prietto to its Executive Team as Vice President of Marketing
enVVeno Medical Corporation announces Sandy Prietto as new VP of Marketing, bringing significant MedTech marketing experience focused on Cardiovascular Devices. Company prepares for VenoValve monetization with upcoming milestones in 2024

VenoValve 2024 Milestones EnVVeno Medical Corporation Sandy Prietto VP Of Marketing
BRIEF

published on 08/14/2024 at 15:05, 8 months 13 days ago

EnVVeno Medical Updates on FDA Premarket Approval for VenoValve®

Medical Device FDA Approval EnVVeno Medical VenoValve CVI Treatment
PRESS RELEASE

published on 08/14/2024 at 15:00, 8 months 13 days ago

enVVeno Medical Provides Update on FDA Premarket Approval Application Status for VenoValve(R)
enVVeno Medical Corporation provides update on VenoValve PMA approval application process for FDA. Company aims to file final module in Q4 2024 after approval of 4 modules

FDA VenoValve EnVVeno Medical Corporation PMA CVI

Accesswire

Published on 04/26/2025 at 02:00, 1 day 15 hours ago

Battery X Metals Announces Strategic Agreement to Advance Artificial Intelligence-Driven Exploration of Critical Battery Metals in Nevada, USA
Published on 04/25/2025 at 23:30, 1 day 17 hours ago

AIML Innovations Announces Departure of Tim Daniels from Board of Directors
Published on 04/25/2025 at 23:01, 1 day 18 hours ago

Medicure Reports Financial Results for Quarter and Year Ended December 31, 2024
Published on 04/25/2025 at 23:00, 1 day 18 hours ago

AIML Optimizes Quantum Sciences Acquisition to Drive Growth & Strategic Focus
Published on 04/25/2025 at 22:15, 1 day 19 hours ago

Grande Portage Resources Announces Extension of Expiry Date for Warrants

View all ACCESSWIRE

EQS Group

Published on 04/25/2025 at 22:47, 1 day 18 hours ago

DEAG achieves new revenue level in “transformation year” 2024 – Strategic investments and strong start to the year create basis for future sustainable growth
Published on 04/25/2025 at 20:30, 1 day 20 hours ago

EQS-Adhoc: Nagarro SE: Confirms 2024 guidance and dividend, postpones publication for full-year results
Published on 04/25/2025 at 18:44, 1 day 22 hours ago

Turkiye Garanti Bankasi A.S.: CMB Approval for Bond Issuance to Foreign Markets
Published on 04/25/2025 at 18:31, 1 day 22 hours ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 04/25/2025 at 18:30, 1 day 22 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 04/25/2025 at 18:16, 1 day 23 hours ago

PR_Carrefour Brazil_25042025
Published on 04/25/2025 at 18:05, 1 day 23 hours ago

Louis Hachette Group - 2025 First-quarter revenue
Published on 04/25/2025 at 18:00, 1 day 23 hours ago

Availability of the 2024 universal registration document
Published on 04/25/2025 at 18:00, 1 day 23 hours ago

Postponement of the publication of the annual financial statements
Published on 04/25/2025 at 17:45, 1 day 23 hours ago

LANSON-BCC: GENERAL SHAREHOLDERS’ MEETING ON APRIL 25, 2025 - DIVIDEND: €0.90 PER SHARE

View all LES ECHOS COMFI WIRE